Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.

Nicum S., Brooks CE., Wharton R., Boyle L., Kaye SB., Gourley C., Hall M., Montes A., Pearson SR., Julier P., Midgley RA., Schuh A., Dutton SJ.

Type

Journal article

Publication Date

2013-01-01T00:00:00+00:00

Volume

31

Permalink Close